阿托伐他汀联合依折麦布在冠心病合并高脂血症患者中的应用研究  

Application of Atorvastatin Combined with Ezemaibu in Patients with Coronary Heart Disease Complicated with Hyperlipidemia

作　　者：刘红果 邓立菊 LIU Hong-guo;DENG Li-ju(Department of Cardiology,Yinan People's Hospital,Linyi,Shandong Province,276300 China)

机构地区：[1]山东省沂南县人民医院心内一科,山东临沂276300

出　　处：《中外医疗》2020年第5期91-93,共3页China & Foreign Medical Treatment

摘　　要：目的探讨阿托伐他汀联合依折麦布在冠心病合并高脂血症患者中的应用。方法便利选择2017年5月-2018年12月冠心病合并高脂血症患者86例作为对象,随机分为对照组(n=43例)和观察组(n=43例)。对照组采用阿托伐他汀治疗,观察组在对照组基础上联合依折麦布治疗,1个月治疗后对患者效果进行评估,比较两组血脂水平、心血管不良事件及药物不良反应发生率。结果观察组治疗后1个月血脂TC为(3.29±0.29)mmol/L、TG(1.21±0.23)mmol/L、LDL-C水平为(2.58±0.23)mmol/L,均低于对照组(t=6.392、8.461、5.309,P<0.05);观察组治疗后1个月HDL-C水平(1.75±0.51)mmol/L,高于对照组(t=5.216,P=0.000);观察组治疗后1个月心源性死亡、心肌梗死、缺血性脑卒中发生率,分别为0.00%、0.00%、2.33%低于对照组6.78%、9.30%、11.63%(χ~2=5.398、7.431、6.412,P=0.025、0.017、0.022)。结论阿托伐他汀联合依折麦布用于冠心病合并高脂血症患者中能降低患者血脂水平,能降低心血管不良事件发生率,未增加药物不良反应发生率。Objective To explore the application of atorvastatin combined with ezetimibe in patients with coronary heart disease and hyperlipidemia. Methods 86 patients with CHD and hyperlipidemia from May 2017 to December 2018 were convenienty divided into control group(n=43 cases) and observation group(n=43 cases). The control group was treated with atorvastatin, while the observation group was treated with ezetimibe on the basis of the control group. After one month of treatment, the effect of patients was evaluated. The blood lipid level, adverse cardiovascular events and adverse drug reactions were compared between the two groups. Results 1 month after treatment, the serum lipids in the observation group were(3.29±0.29) mmol/L, TG(1.21±0.23) mmol/L and ldl-c levels were(2.58±0.23) mmol/L, which were lower than those in the control group(t=6.392, 8.461, 5.309, P<0.05). The hdl-c level(1.75±0.51) mmol/L in the observation group was higher than that in the control group(t=5.216, P =0.000) one month after treatment. The incidence of cardiogenic death,myocardial infarction and ischemic stroke in the observation group was 0.00%, 0.00%, 2.33%, lower than that in the control group 6.78%, 9.30%, 11.63%(χ~2=5.398, 7.431, 6.412, P =0.025, 0.017, 0.022). Conclusion Atorvastatin combined with ezetimibe in patients with coronary heart disease and hyperlipidemia can reduce blood lipid levels, reduce the incidence of cardiovascular adverse events, and do not increase the incidence of adverse drug reactions.

关 键 词：阿托伐他汀 依折麦布 冠心病 高脂血症 血脂水平 

分 类 号：R541.4[医药卫生—心血管疾病] R589.2[医药卫生—内科学]